Omeros Corporation (NASDAQ:OMER – Get Free Report) Director Thomas Cable sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the transaction, the director directly owned 35,067 shares of the company’s stock, valued at $646,986.15. The trade was a 29.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Omeros Stock Performance
Omeros stock opened at $19.27 on Friday. The company has a market capitalization of $1.39 billion, a PE ratio of 15.05 and a beta of 2.54. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $19.58. The firm has a 50 day moving average price of $11.73 and a 200 day moving average price of $11.76.
Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
OMER has been the subject of several research reports. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.00.
Get Our Latest Report on Omeros
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
- Five stocks we like better than Omeros
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
